In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients
1998

Low-Dose IL-2 and IL-12 Secretion in Metastatic Cancer Patients

Sample size: 19 publication Evidence: moderate

Author Information

Author(s): P Lissoni, L Fumagalli, F Rovel, F Briviol, G Di Felice, F Majorca

Primary Institution: San Gerardo Hospital, Monza, Milan, Italy

Hypothesis

Does subcutaneous low-dose IL-2 stimulate IL-12 secretion in metastatic cancer patients?

Conclusion

Low-dose IL-2 immunotherapy may stimulate the in vivo release of IL-12, which is associated with a favorable prognosis.

Supporting Evidence

  • IL-2 injection significantly increased IL-12 levels in patients with stable disease or response.
  • Patients with high pretreatment IL-12 levels had a higher rate of disease progression.
  • 10 out of 12 patients with response or stable disease showed an increase in IL-12 levels greater than 50%.

Takeaway

This study found that giving a small dose of a treatment called IL-2 can help the body produce a substance called IL-12, which might help fight cancer better.

Methodology

The study involved 19 metastatic renal cell cancer patients receiving low-dose IL-2, with serum IL-12 levels measured before and during treatment.

Limitations

The study had a small sample size and only included one type of cancer.

Participant Demographics

20 metastatic renal cell cancer patients (14 males, 6 females; median age 61 years).

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication